Trial Profile

A Single-Dose Study Using Functional Magnetic Resonance Imaging to Evaluate the Effect of LY3154207 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mevidalen (Primary)
Indications Dementia; Lewy body disease; Parkinson's disease
Focus Pharmacodynamics
Sponsors Eli Lilly and Company

Most Recent Events

21 Feb 2022 Status changed from recruiting to completed.
16 Dec 2021 Planned number of patients changed from 34 to 15.
02 Sep 2021 Planned End Date changed from 30 Nov 2021 to 31 Mar 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com